
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefinewhat’spossible.
Kyverna is seeking a Director of Training, Global Medical Affairs, responsible for designing and leading a comprehensive, phase-appropriate training strategy to support highly specialized Medical and Commercial field teams responsible for commercializing miv-cel and other pipeline assets. The Director will build a training infrastructure that ensures Medical and Commercial teams are scientifically rigorous, operationally fluent, and compliant in highly regulated, chain-of-identity–dependent treatment models. The successful candidate will establish scalable onboarding, certification, and continuous capability development programs that integrate clinical science, CMC fundamentals, and post-marketing surveillance obligations unique to advanced therapies.
Department: Medical Affairs
Reports to: Sr. Scientific Director, Medical Affairs
Location: Remote
Travel: Approximately 15%
The national salary range for this position is from $210,000 to $245,000 USD annually. This salary range is an estimate of what we reasonably expect to pay for this posted position, and the actual salary may vary based on various factors, including without limitation individual education, experience, tenure, skills and abilities, as well as internal equity and alignment with market data. This position is also eligible for bonus, benefits, and participation in Company’s stock plan.

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.